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Statin Inhibition of Fc Receptor–Mediated Phagocytosis
by Macrophages Is Modulated by Cell Activation
and Cholesterol
J.D. Loike, D.Y. Shabtai, R. Neuhut, S. Malitzky, E. Lu, J. Husemann, I.J. Goldberg, S.C. Silverstein
Objectives—An inflammatory response to altered lipoproteins that accumulate in the arterial wall is a major component of
the pathogenesis of atherosclerosis. Statins reduce plasma levels of low-density lipoprotein (LDL) and are effective
treatments for atherosclerosis. It is hypothesized that they also modulate inflammation. The aim of this study was to
examine whether lovastatin inhibits macrophage inflammatory processes and clarify its mechanism of action.
Methods and Results—We examined the effects of statins on phagocytosis of antibody-coated red blood cells by cultured
human monocytes and mouse peritoneal macrophages. Lovastatin, simvastatin, and zaragozic acid, a squalene synthase
inhibitor, blocked Fc receptor–mediated phagocytosis by cultured human monocytes and mouse peritoneal macro-
phages. The inhibitory effect of lovastatin on Fc receptor–mediated phagocytosis was prevented completely by addition
of mevalonate, farnesyl pyrophosphate, LDL, or cholesterol to the culture medium. The inhibitory effect of zaragozic
acid was reversed by addition of LDL, but not by the addition of geranylgeranyl pyrophosphate, to the medium. In
addition, the effect of lovastatin on phagocytosis is a function of cell activation because treatment of cells with tumor
necrosis factor- or lipopolysaccharide prevented inhibition of phagocytosis by lovastatin.
Conclusions—The inhibition of Fc receptor–mediated phagocytosis of lovastatin is related to its effect on cholesterol
biosynthesis rather than its effect on the formation of isoprenoids. (Arterioscler Thromb Vasc Biol. 2004;
24:2051-2056.)
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Atherosclerosis is thought to be mediated by an inflam-matory response to the deposition of lipoproteins and
altered lipids in the arterial wall.1 Atherogenesis involves the
migration of monocytes into the subendothelial space,2 where
they adhere to matrices containing oxidized low-density
lipoprotein (LDL), mature into macrophages, and secrete
growth factors, proteases, and reactive oxygen species.3 Since
their introduction into clinical practice, 3-hydroxy-3-methyl-
glutaryl–coenzyme A (HMG-CoA) reductase inhibitors, or
statins, have had a profound effect on preventing and treating
atherosclerosis.4 By competitively inhibiting HMG-CoA re-
ductase, the rate-limiting enzyme of cholesterol biosynthesis,
statins block mevalonate generation and subsequent choles-
terol synthesis. By lowering cellular cholesterol concentra-
tion, statins upregulate hepatic LDL receptors, thereby low-
ering plasma LDL levels 50%.
However, some of the biochemical effects of statins have
been postulated to be independent of their lipid-lowering
effects.5 Multiple reports document the anti-inflammatory
effects of statins under in vivo and in vitro conditions. Statins
suppress expression of proinflammatory chemokines, chemo-
kine receptors, cytokines,6 reduce plasma levels of C-reactive
protein,7 and P-selectin,8 inhibit leukocyte adhesion,9,10
downregulate scavenger receptor A,11 and blunt the respira-
tory burst of monocytes.12 Statins also prolong the survival of
lung, renal, and cardiac allografts.13,14
Anti-inflammatory properties of statins may be attributable
to their effects on protein isoprenylation. At very high
concentrations, statins block formation of the isoprenyl lipids
farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophos-
phate (GGPP),15 thereby inhibiting the prenylation of proteins
such as GTPases.16–18 GTPases regulate many macrophage
actions such as phagocytosis, and prenylation is required for
their activity.19,20
We report here that lovastatin inhibits one inflammatory
process: receptor-mediated phagocytosis. Contrary to our
expectations, reduction of cellular cholesterol by zaragozic
acid A (ZA), a squalene synthase inhibitor,21 as well as
lovastatin, reduced Fc receptor–mediated phagocytosis of
IgG antibody–coated sheep red blood cells [E(IgG)] by
human monocytes and mouse peritoneal macrophages. How-
ever, the inhibitory effect of lovastatin on Fc receptor–
mediated phagocytosis was not a result of its capacity to
block prenylation; rather, it was attributable to its capacity to
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inhibit cholesterol biosynthesis. Furthermore, tumor necrosis
factor- (TNF-) or lipopolysaccharide (LPS) treatment pre-
vented and reversed lovastatin-mediated inhibition of Fc
receptor–mediated phagocytosis in the absence of added
cholesterol. These findings indicate that cellular cholesterol
regulates Fc receptor–mediated phagocytosis, and TNF- and
LPS stimulation overcome inhibition of lovastatin.
Materials and Methods
Human Monocytes
Monocyte-enriched cell preparations were isolated from the blood of
healthy volunteers (none were taking statins) after informed consent
as described.22,23 Briefly, human mononuclear cells were isolated
from freshly drawn blood by centrifugation over Histopaque-1077
(Sigma-Aldrich) as described previously.22,23 Cells were washed 3
in RPMI medium 1640 (Life Technologies BRL) containing peni-
cillin (140 U/mL) and streptomycin (140 g/mL; Gibco BRL) by
centrifugation at 1500 rpm for 10 minutes. After washing, they were
resuspended in RPMI complete medium (RPMI medium 1640,
penicillin [140 U/mL], streptomycin [140 g/mL], and 10% heat-
inactivated FBS [Gibco]). Monocyte-enriched cell preparations were
suspended at 2 to 3 million cells per milliliter in RPMI medium 1640
and incubated on glass coverslips (12-mm diameter) at 37°C for 1
hour in 24-well culture dishes. Coverslips then were washed with
PBS containing 1 mmol/L CaCl2 and 0.5 mmol/L MgCl2 to remove
nonadherent cells, incubated with 0.5 mL of RPMI medium 1640,
and incubated overnight at 37°C in the same medium. The adherent
cells (200 000 to 300 000 per coverslip) were 95% monocytes as
measured by their phagocytic capacity to ingest E(IgG).
Mouse Peritoneal Macrophages
Resident peritoneal cells were isolated from C57BL/126 mice 8 to 12
weeks of age as described.24 Twenty-nine percent (3%) of these
cells were macrophages, as indicated by their expression of nonspe-
cific esterase and endocytosis of 1,1-dioctadecyl-3,3,3,3tetrameth-
ylindocarbocyanine perchlorate–labeled acetylated LDL.22 Cells
were allowed to adhere to 12-mm glass coverslips for 2 hours, and all
nonadherent cells were removed by washing with RPMI medium
1640 maintained as described for human monocytes. Adherent cells
were 99% macrophages as described.22
IgG-Opsonized Sheep Red Blood Cells
Sheep red blood cells (Hardy Diagnostics) were opsonized with
rabbit anti-sheep red blood cell IgG antibody (Cappel) as described.24
Phagocytosis Assay
Freshly isolated human monocytes or mouse peritoneal macrophages
maintained on glass coverslips were incubated overnight at 37°C.
Coverslips were then washed once in PBS containing 0.1% (wt/vol)
human serum albumin and 5.5 mmol/L glucose, overlaid with 15 L
of E(IgG) in PBS, and incubated at 37°C for 1 to 2 hours, dipped 5
in PBS to remove excess E(IgG), 6 in distilled water to lyse the
extracellular E(IgG), and an additional 5 in PBS, all as described,24
mounted on glass slides, and viewed by light microscopy using a
40 lens. Intracellular E(IgG) appeared as phase dense spheres as
described.24 Phagocytic Index (PI) is the average number of E(IgG)
ingested per 100 macrophages. To access the total number of
attached and ingested E(IgG) per 100 macrophages, cells were
washed only in PBS without lysing the extracellular E(IgG) in water
and viewed under the microscope.
Fluid Phase Pinocytosis
Fluid phase pinocytosis was measured using Lucifer yellow as
described.25 Briefly, monocytes cultured for 24 hours were further
incubated in 300 L PBS containing 0.5 mg/mL Lucifer yellow,
0.1% human serum albumin, and 5.5 mmol/L glucose for the
indicated time periods. The medium was removed and adherent cells
were washed 6 in PBS at 4°C. To lyse the cells, 500 L of water
containing Triton X-100 (0.05%) was added to each well, and
fluorescence was measured on a cell plate reader using excitation of
485 nm, emission at 530 nm. Standard curves for solutions contain-
ing known concentrations of Lucifer yellow were prepared and found
to be linear from 0.05 to 100 ng/mL.
Reagents
Lovastatin in its active form was from A.G. Scientific, and simva-
statin and ZA were obtained from Merck Sharp & Dohme. Statins
were all dissolved and stored in dimethyl sulfoxide (DMSO) and
diluted 1000-fold in RPMI medium 1640 immediately before they
were added to the cells. TNF- was obtained from Upstate Biotech-
nology Co. All other reagents were from Sigma Chemical Co.
Results
Lovastatin and Simvastatin Inhibit Fc
Receptor–Mediated Phagocytosis by Mouse
Peritoneal Macrophages and Cultured
Human Monocytes
Mouse peritoneal macrophages and cultured human mono-
cytes adherent to glass coverslips were incubated at 37°C
for 24 hours in medium containing 10% FBS without or
with lovastatin or simvastatin at the concentrations indi-
cated (Figures 1 and 2), washed, and then incubated at
37°C in PBS containing 10% FBS, 5.5 mmol/L glucose,
and statin as indicated E(IgG), for an additional 2 hours. In
medium without statins, mouse macrophages ingested an
Figure 1. Lovastatin and simvastatin inhibit Fc receptor–medi-
ated phagocytosis. Phagocytic indices of mouse peritoneal
macrophages (a) and freshly isolated human monocytes (b)
ingesting E(IgG) in response to increasing concentrations of lov-
astatin and simvastatin. Values represent meanSEM; n3.
Figure 2. Phagocytosis by mouse peritoneal macrophages.
Phase micrographs comparing phagocytosis of E(IgG) by mouse
peritoneal macrophages maintained for 24 hours in medium
containing no additions (left) and 10 mol/L lovastatin (right).
Before E(IgG) were added, macrophages were equally spread in
both conditions.
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average of 6 E(IgG) each (ie, PI of 600) with some
macrophages ingesting as many as 10 (Figures 1 and 2).
Lovastatin and simvastatin were equally effective in inhib-
iting E(IgG) ingestion by mouse macrophages. At 5 and
10 mol/L, both drugs inhibited E(IgG) uptake by mouse
macrophages 45% and 70%, respectively (Figure 1).
Although most lovastatin-treated murine macrophages in-
gested 2 to 3 E(IgG), occasionally, we observed lova-
statin-treated macrophages that had ingested 4 to 6 E(IgG)
(Figure 2). Untreated cultured human monocytes ingested
an average of 2 to 3 E(IgG) each (ie, PI of 260) and 5 and
10 mol/L of lovastatin and simvastatin inhibited E(IgG)
uptake by cultured human monocytes 57% and 70%,
respectively (Figure 1). Control experiments confirmed
that mouse macrophages and human monocytes ingested
few, if any, unopsonized erythrocytes (data not shown;24)
and that lovastatin (10 mol/L) had no adverse effects on
attachment of E(IgG) to these cells, on the number of cells
adherent to glass coverslips, and on cell viability, as
measured by trypan blue dye exclusion (data not shown).
Lovastatin Has No Effect on Fluid
Phase Endocytosis
Because membrane fluidity and movement are required for
all endocytic events, we examined whether lovastatin affects
fluid phase endocytosis, a process that occurs in macrophages
via clathrin-dependent and clathrin-independent mecha-
nisms.26 Human monocytes (106 cells per well) were incu-
bated overnight in 24-well plates in RPMI medium 1640 in
the absence or presence of lovastatin (1 to 10 mol/L).
Lucifer yellow was added to the medium, the cells were
incubated for an additional 120 minutes, and the amount of
Lucifer yellow taken up by the cells was assayed as described
in Materials and Methods. The amount of Lucifer yellow
taken up under all conditions was the same (1.70.2 for
untreated cells and 1.80.4 pmol per 2 hours for cells treated
with 10 mol/L lovastatin). Thus, maintenance of cultured
human monocytes in medium containing 1 to 10 mol/L
lovastatin for 24 hours had no effect on fluid phase endocy-
tosis (data not shown).
Lovastatin Inhibits Fc Receptor–Mediated
Phagocytosis by Blocking HMG-CoA Reductase
Inhibition of HMG-CoA reductase by statins alters a number
of downstream pathways, including biosynthesis of isoprenyl
lipids and cholesterol (Figure 3). Therefore, we used various
agents to differentiate between these pathways.
To confirm that the effect of lovastatin on phagocytosis
was attributable to its inhibitory effect on HMG-CoA reduc-
tase and not a result of pleiotrophic effects, we incubated
human cultured monocytes in medium containing meval-
onate, the immediate product of HMG-CoA reductase, or in
medium containing FPP, a precursor of cholesterol and
isoprenyl lipids (Figure 3). Mevalonate and FPP blocked the
inhibitory effect of lovastatin on phagocytosis of E(IgG)
(Figure 4a and 4b).
Cholesterol-Containing Lipoproteins, Cholesterol,
and Biosynthetic Precursors of Cholesterol Prevent
Inhibitory Effects of Lovastatin on Phagocytosis
of E(IgG)
Mevalonate and FPP are precursors of cholesterol and of
isoprenyl lipids. To determine whether lovastatin inhibited
phagocytosis by blocking the synthesis of cholesterol, isoprenyl
lipids, or both, we compared E(IgG) phagocytosis by monocytes
incubated for 24 hours in medium containing 10 mol/L
lovastatin alone versus medium containing 10 mol/L lovastatin
and 100 mol/L cholesterol,27 or 10 mol/L lovastatin and 100
g/mL LDL. Addition of cholesterol or LDL completely
blocked the inhibitory effect of lovastatin on E(IgG) uptake
(Figure 4a). These results suggested that lovastatin inhibits Fc
receptor–mediated phagocytosis by depriving monocytes of
cholesterol.
ZA Inhibits Phagocytosis of E(IgG) by
Cultured Monocytes
Squalene synthase catalyzes the formation of squalene, a
cholesterol precursor, from FPP (Figure 3). Moreover, the
squalene synthase inhibitor ZA stimulates FPP synthesis,
thereby increasing its availability, and the availability of other
Figure 3. Biosynthesis of cholesterol.
Figure 4. Inhibition of Fc receptor–mediated phagocytosis by
lovastatin is reversed completely by mevalonate, LDL, cholester-
ol, or FPP. a, E(IgG) phagocytosis by freshly isolated human
monocytes treated overnight with medium containing DMSO
(control), 100 mol/L mevalonate, 100 g/mL LDL, or
100 mol/L cholesterol with or without 10 mol/L lovastatin.
Values represent meanSEM; n5. b, E(IgG) phagocytosis by
freshly isolated human monocytes incubated overnight in
medium containing DMSO or 10 mol/L FPP with or without
10 mol/L lovastatin. Values represent meanSEM; n5. Stu-
dent t test analysis (P0.05) determined that lovastatin inhibited
phagocytosis and that LDL, cholesterol, mevalonate, and FPP
significantly blocked the inhibitory effect of lovastatin.
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isoprenyl lipids derived from it (eg, GGPP), to isoprenylate
small GTPases.16,19,20 Therefore, we incubated cultured hu-
man monocytes in medium containing 5 mol/L ZA, a
concentration vastly in excess of that required to inhibit rat
liver squalene synthase,21 to further test the hypothesis that
cholesterol is required for E(IgG) phagocytosis. ZA inhibited
phagocytosis of E(IgG) by 40% (Figure 5), a value similar to
that obtained with lovastatin alone. The finding that 5 mol/L
ZA in combination with 10 mol/L lovastatin was not a
better inhibitor of E(IgG) phagocytosis than ZA alone (Figure
5) suggests that increased availability of isoprenyl lipids in
ZA-treated cells played no role in the extent to which ZA
inhibited E(IgG) uptake (Figure 5). Rather, cholesterol is
required for Fc receptor–mediated phagocytosis of E(IgG).
The conclusion that ZA inhibits Fc receptor–mediated phago-
cytosis of E(IgG) by blocking cholesterol synthesis was
further buttressed by the finding that the inhibitory effect of
ZA on E(IgG) phagocytosis was unaffected by the addition
of 100 mol/L GGPP to the medium but was completely
prevented by addition of 100 g LDL to the medium (Figure
5). GGPP does not contribute to cholesterol biosynthesis
but is a precursor for the production of isoprenyl products
(Figure 3).
TNF- and LPS Prevent and Reverse the
Inhibitory Effect of Lovastatin on Fc
Receptor–Mediated Phagocytosis
The experiments described up to this point used monocytes
cultured in medium lacking added growth factors and cyto-
kines. However, monocytes and macrophages are exposed to
bacterial products (eg, LPS) and cytokines (eg, TNF-,
interleukin-1, interferon- [INF-]) when they enter sites of
infection or inflammation in vivo. Therefore, we examined
the effects of LPS and TNF- on lovastatin-mediated inhibi-
tion of E(IgG) phagocytosis. We observed that monocytes
incubated in medium containing 10 mol/L lovastatin and
either 10 ng/mL LPS or 100 ng/mL TNF- for 24 hours
phagocytosed E(IgG) as efficiently as cells treated with LPS
or TNF- alone (Figure 6). In contrast, other proinflamma-
tory substances such as formyl-methionyl-leucyl-
phenylalanine (fMLP) and leukotriene B4 (LTB4), which
stimulate monocytes by activating their heptahelical Gi-
coupled receptors, had no effect on the ability of lovastatin to
inhibit phagocytosis (Figure 6). In addition, when cells were
treated with lovastatin (5 mol/L) for 24 hours and then
further incubated in medium containing lovastatin and either
TNF- or LPS for 4 hours, we observed complete reversal of
the inhibitory effect of lovastatin on phagocytosis (data not
shown).
Discussion
Statins have a number of important pharmacological effects
in addition to reducing plasma LDL levels. Pursuing the
widespread belief that statins exert anti-inflammatory effects,
we found that lovastatin and simvastatin inhibit macrophage
phagocytosis of E(IgG) but do not affect endocytosis of
soluble substances. Three lines of evidence indicate that
lovastatin inhibits Fc receptor–mediated phagocytosis by
blocking cellular cholesterol synthesis and not by blocking
synthesis of isoprenyl lipids. First, the inhibitory effect of
lovastatin is prevented by addition of LDL or cholesterol
(Figure 4) but not of GGPP (Figure 5) to the medium. Second,
ZA, which inhibits synthesis of cholesterol but not of isopre-
nyl lipids, blocked Fc receptor–mediated phagocytosis to
about the same extent as lovastatin (Figure 5). The inhibitory
effect of ZA also was prevented and reversed by addition of
LDL but not of GGPP to the medium (Figure 5). Third, ZA
and lovastatin in combination were no more potent in
inhibiting phagocytosis than either drug alone (Figure 5),
suggesting they act by a common mechanism (ie, by inhib-
iting cholesterol synthesis).
Macrophages often function in regions that are rich in
proinflammatory cytokines (eg, atherosclerotic plaques). For
this reason, we tested the effects of TNF- and LPS,
Figure 5. Effects of zaragozic acid on Fc receptor–mediated
phagocytosis. Freshly isolated human monocytes were incu-
bated for 24 hours with the indicated inhibitors in the presence
or absence of GGPP or LDL as indicated. Cells were washed
and further incubated with E(IgG) under the conditions indi-
cated. Phagocytic indices were assessed as described in Mate-
rials and Methods. Values shown are the percentage of
controlSEM; n3. Student t test analysis (P0.05) determined
that ZA and lovastatin inhibited phagocytosis and that LDL sig-
nificantly blocked the effect of ZA on phagocytosis.
Figure 6. TNF- and LPS prevent the inhibitory effect of lova-
statin on Fc receptor–mediated phagocytosis of E(IgG) by
human monocytes. Freshly isolated human monocytes were
incubated for 24 hours in medium containing either 107 mol/L
fMLP, 107 mol/L LTB4, 100 ng/mL of TNF-, or 10 ng/mL of
LPS in the presence or absence of 10 mol/L lovastatin, as
indicated. Cells then were washed and reincubated under the
indicated conditions with the addition of E(IgG), and their
phagocytic indices were assessed. Values shown are the per-
centage of controlSEM; n3. Student t test analysis (P0.05)
determined that lovastatin inhibited phagocytosis and that LPS
and TNF significantly blocked the inhibitory effect of lovastatin
on phagocytosis.
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proinflammatory substances found in blood.19 Bacterial in-
fection is associated with increased risk of coronary heart
disease,28,29 and TNF- is found within atherosclerotic le-
sions.30 TNF- and LPS prevented and reversed the inhibi-
tory effect of lovastatin on E(IgG) phagocytosis (Figure 6;
data not shown), suggesting that these substances activate
pathways that override the effects of cholesterol depletion.
Endogenous Synthesis Is the Primary Source of
Cholesterol in Monocytes/Macrophages
Maintained in Medium Containing FBS
Mammalian cells, including monocytes and macrophages,
obtain cholesterol from 2 sources: circulating lipoproteins
and de novo synthesis. In our experiments, monocytes and
macrophages were maintained in medium containing 10%
FBS. Because FBS contains very little cholesterol, monocytes
and macrophages maintained in FBS rely primarily on syn-
thesis to obtain the cholesterol they require. Indeed, it seems
likely that even in the absence of inhibitors, endogenous
cholesterol synthesis was less than optimal. This is probably
the reason that addition of mevalonate to the culture medium
enhanced E(IgG) phagocytosis by 20% to 30% (Figure 4a).
Fc receptor–mediated phagocytosis of E(IgG) requires the
coordinated movement of membranes and cytoplasm.31 Cho-
lesterol is required for plasma membrane formation and for
the activity of many plasma membrane signaling pathways,
including Fc receptor signaling.32 There are 2 principle
mechanisms by which reductions in cellular cholesterol might
affect Fc receptor–mediated phagocytosis. First, by depleting
mononuclear phagocytes of cholesterol, lovastatin and ZA
may impede Fc receptor redistribution into cholesterol-rich
lipid rafts. By this means, these drugs may reduce Fc receptor
cross-linking, tyrosine kinase activation, and actin filament
assembly,32 and thereby inhibit phagocytosis. In fact, recent
studies by Hillyard et al show that fluvastatin at micromolar
concentrations inhibited Fc receptor signal transduction in
human monocytes at the level of tyrosine kinase activation in
a time- and dose-dependent manner.33
A second mechanism by which lovastatin and ZA may
inhibit Fc receptor–mediated phagocytosis is by interfering
with plasma membrane biosynthesis, thereby reducing the
availability of macrophage plasma membrane stores. Green-
berg et al31 have reported that insertion of plasma membrane
from internal stores is required for efficient phagocytosis of
E(IgG) by macrophages. Our finding that TNF- and LPS
reverse the inhibitory effect of lovastatin on phagocytosis
within a few hours of their addition to the medium (Figure 6;
data not shown) suggests that lack of availability of internal
plasma membrane stores is not the principal mechanism by
which lovastatin blocks phagocytosis of E(IgG).
Our studies provide several insights that are relevant to the
reported inhibitory effects of statins on mononuclear phago-
cyte functions in vitro and in vivo. First, they show that
statins exert a powerful inhibitory effect on one of the
cardinal functions of mononuclear phagocytes (Fc receptor–
mediated phagocytosis) when these cells are maintained in
medium lacking cholesterol or LDL. Second, they demon-
strate that in medium containing cholesterol or a subphysio-
logical concentration of LDL (ie, 100 g/mL), lovastatin
does not inhibit phagocytosis, even when used at 10 mol/L
(Figure 4). The peak plasma lovastatin concentration in
patients taking this drug orally ranges between 0.2 and
1 mol/L. At these concentrations, lovastatin had an insig-
nificant effect on E(IgG) phagocytosis (Figure 1). This
suggests that under physiological conditions in which LDL
concentrations generally exceed 1 mg/mL, statin-mediated
inhibition of endogenous cholesterol synthesis by mononu-
clear phagocytes is unlikely to affect the functions of these
cells. Third, they show that even in LDL-free medium,
proinflammatory cytokines (eg, TNF-) and bacterial prod-
ucts (eg, LPS) can overcome the inhibitory effect of lovastat-
in on phagocytosis. TNF- and LPS are likely to exert similar
effects in vivo in tissues containing very low concentrations
of LDL (eg, cerebrospinal fluid, airways, and joint spaces).
This is consistent with clinical observations that patients
taking statins show no defects in wound healing or in
combating bacterial infections.
Do Statins Affect Inflammation?
It has been postulated that statins provide beneficial anti-
inflammatory effects exclusive of cholesterol lowering;34
however, this conclusion is controversial.35 There are limited
data that other more clearly defined anti-inflammatory drugs
affect the progression of atherosclerosis. Comparisons of
multiple intervention trials for coronary artery disease show
declines in disease that correlate with the degree of choles-
terol reduction, whether this is achieved by statins or other
methods.36 The reduction in plasma C-reactive protein, pro-
duced primarily in the liver, that occurs in patients treated
with statins has been interpreted as evidence of an anti-
inflammatory effect of these drugs.1 It is uncertain whether
this reduction is due specifically to statins or the concomitant
cholesterol reduction. Reduction of plasma cholesterol or
LDL itself may reduce some inflammatory processes.34
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